Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma.
Vanderbilt University Medical Center, Nashville, TN douglas.b.johnson@vanderbilt.edu.
Douglas B
DB
Johnson
H. Lee Moffitt Cancer Center, Tampa, FL.
Vita
V
Saranga-Perry
Vanderbilt University Medical Center, Nashville, TN.
Patrick J M
PJ
Lavin
Vanderbilt University Medical Center, Nashville, TN.
W Bryan
WB
Burnette
Vanderbilt University Medical Center, Nashville, TN.
Stephen W
SW
Clark
Vanderbilt University Medical Center, Nashville, TN.
David R
DR
Uskavitch
Vanderbilt University Medical Center, Nashville, TN.
Deborah E
DE
Wallace
Memorial Sloan Kettering Cancer Center, New York, NY.
Mark A
MA
Dickson
H. Lee Moffitt Cancer Center, Tampa, FL.
Ragini R
RR
Kudchadkar
Vanderbilt University Medical Center, Nashville, TN.
Jeffrey A
JA
Sosman
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D008775:Methylprednisolone / Q000627:therapeutic use; D009157:Myasthenia Gravis / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D010956:Plasmapheresis / Q000379:methods; D018570:Risk Assessment; D012494:Sampling Studies; D012720:Severity of Illness Index; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D015996:Survival Rate; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000074324:Ipilimumab; D008775:Methylprednisolone